Pharmaceutical Prices Creep Upwards In H111, But Austerity Pressures Limit Inflation

BMI view: Deficits remain a key challenge for the majority of governments across Europe. While many sectors may see only limited downside risks from the situation, the pharmaceutical industry is facing considerable pressures as the structure of pharmaceutical payments in Europe makes the industry more vulnerable to fiscal austerity measures than elsewhere. As predicted by BMI, the dire fiscal situations facing many of these countries have necessitated the introduction of harsher price erosion mechanisms across Europe.

To read the full article, please choose one of the following options: